Physician profile
Amy Penticuff
NPI 1962058446
$3,889.81
in general payments reported to CMS, 2019-2025
20 companies · $826 in 2025
The $826 reported for 2025 was more than what 77% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $766 · 2022: $1,001 · 2023: $372 · 2024: $926 · 2025: $826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,123.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $730.75 | 2021-2025 | Caplyta |
| Abbvie INC. | $511.85 | 2021-2025 | |
| Alkermes, INC. | $324.90 | 2021-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $301.72 | 2022-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $301.28 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lundbeck LLC | $276.73 | 2021-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $263.71 | 2021-2025 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $241.57 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $199.01 | 2023-2025 | Auvelity |
| Corium, LLC | $174.88 | 2021-2025 | Azstarys |
| Bausch Health US, LLC | $104.10 | 2022-2025 | Wellbutrin, Aplenzin |
| Sunovion Pharmaceuticals INC. | $88.96 | 2022 | |
| Janssen Pharmaceuticals, INC | $86.85 | 2021-2023 | Spravato |
| Neurocrine Biosciences, INC. | $62.94 | 2021-2025 | Ingrezza |
| Collegium Pharmaceutical, INC. | $58.88 | 2025 | Jornay Pm |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $56.45 | 2023-2025 | Xelstrym |
| Ironshore Pharmaceuticals INC. | $44.88 | 2021-2023 | Jornay Pm |
| Tris Pharma INC | $24.10 | 2024 | Dyanavel Xr |
| Jazz Pharmaceuticals INC. | $22.86 | 2022 | |
| Neos Therapeutics, LP | $13.39 | 2023 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Penticuff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.